PMID- 31160270
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20210117
IS  - 2352-3964 (Electronic)
IS  - 2352-3964 (Linking)
VI  - 44
DP  - 2019 Jun
TI  - The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and 
      metastasis of NSCLC cells by sponging miR-96-5p.
PG  - 182-193
LID - S2352-3964(19)30340-8 [pii]
LID - 10.1016/j.ebiom.2019.05.032 [doi]
AB  - BACKGROUND: Non-small cell lung carcinomas (NSCLC) are prevalent, lethal cancers 
      with especially grim prospects due to late-stage detection and chemoresistance. 
      Circular RNAs (circRNAs) are non-coding RNAs that participate in tumor 
      development. However, the role of circRNAs in NSCLC is not well known. This study 
      investigated the role of one circRNA - circPTPRA- in NSCLC and characterized its 
      molecular mechanism of action. METHODS: circPTPRA expression was analyzed in 
      human NSCLC tumors and matched healthy lung tissue. We performed functional 
      characterization in NSCLC cell lines and a mouse xenograft model of NSCLC to 
      elucidate the molecular role of circPTPRA in epithelial-mesenchymal transitioning 
      (EMT). We also assessed the regulatory action of circPTPRA on the microRNA 
      miR-96-5p and its target the tumor suppressor Ras association domain-containing 
      protein 8 (RASSF8). FINDINGS: circPTPRA was significantly downregulated in NSCLC 
      tumors relative to matched healthy lung tissue. Lower circPTPRA levels correlated 
      with metastasis and inferior survival outcomes in NSCLC patients. circPTPRA 
      suppressed EMT in NSCLC cell lines and reduced metastasis in the murine xenograft 
      model by sequestering miR-96-5p and upregulating RASSF8. Correlation analyses in 
      patient-derived NSCLC tumor specimens supported the involvement of the 
      circPTPRA/miR-96-5p/RASSF8/E-cadherin axis dysregulation in NSCLC tumor 
      progression. INTERPRETATION: circPTPRA suppresses EMT and metastasis of NSCLC 
      cell lines by sponging miR-96-5p, which upregulates the downstream tumor 
      suppressor RASSF8. The circPTPRA/miR-96-5p/RASSF8/E-cadherin axis can be 
      leveraged as a potential treatment avenue in NSCLC. FUND: The Key research and 
      development projects of Anhui Province (201904a0720079), the Natural Science 
      Foundation of Anhui Province (1908085MH240), the Graduate Innovation Program of 
      Bengbu Medical College (Byycx1843), the National Natural Science Foundation of 
      Tibet (XZ2017ZR-ZY033) and the Science and Technology Project of Shannan 
      (SNKJYFJF2017-3) and Academic Subsidy Project for Top Talents in Universities of 
      Anhui in 2019 (gxbjZD16).
CI  - Copyright (c) 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Wei, Siliang
AU  - Wei S
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Zheng, Yuanyuan
AU  - Zheng Y
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Jiang, Yanru
AU  - Jiang Y
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Li, Xiaojun
AU  - Li X
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233004, China.
FAU - Geng, Jian
AU  - Geng J
AD  - Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu 
      233004, China; Anhui Province Key Laboratory of Translational Cancer Research, 
      233004, China.
FAU - Shen, Yuanbing
AU  - Shen Y
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Li, Qin
AU  - Li Q
AD  - Department of Respiratory Disease, The Second Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China.
FAU - Wang, Xiaojing
AU  - Wang X
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Zhao, Chengling
AU  - Zhao C
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Chen, Yuqing
AU  - Chen Y
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China.
FAU - Qian, Zhongqing
AU  - Qian Z
AD  - Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, 
      Anhui 233003, China.
FAU - Zhou, Jihong
AU  - Zhou J
AD  - Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu 
      233004, China; Anhui Province Key Laboratory of Translational Cancer Research, 
      233004, China. Electronic address: zhoujihongww@126.com.
FAU - Li, Wei
AU  - Li W
AD  - Department of Respiratory Disease, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu 233004, China; Provincial Key Laboratory of Respiratory 
      Disease in Anhui, Bengbu 233004, China; Anhui Province Key Laboratory of 
      Translational Cancer Research, 233004, China. Electronic address: 
      bbmcliwei@126.com.
LA  - eng
PT  - Journal Article
DEP - 20190531
PL  - Netherlands
TA  - EBioMedicine
JT  - EBioMedicine
JID - 101647039
RN  - 0 (Cadherins)
RN  - 0 (MIRN96 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - EC 3.1.3.48 (PTPRA protein, human)
RN  - EC 3.1.3.48 (Receptor-Like Protein Tyrosine Phosphatases, Class 4)
SB  - IM
MH  - Animals
MH  - Cadherins/genetics/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/*pathology/therapy
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Epithelial-Mesenchymal Transition/*genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/mortality/*pathology/therapy
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Phenotype
MH  - RNA Interference
MH  - RNA, Circular/*genetics
MH  - Receptor-Like Protein Tyrosine Phosphatases, Class 4/*genetics
PMC - PMC6604667
OTO - NOTNLM
OT  - Epithelial-mesenchymal transition, EMT
OT  - Lung cancer
OT  - NSCLC
OT  - circRNA
OT  - miR-96-5p
EDAT- 2019/06/05 06:00
MHDA- 2019/12/19 06:00
PMCR- 2019/05/31
CRDT- 2019/06/05 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/05/06 00:00 [revised]
PHST- 2019/05/13 00:00 [accepted]
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
PHST- 2019/06/05 06:00 [entrez]
PHST- 2019/05/31 00:00 [pmc-release]
AID - S2352-3964(19)30340-8 [pii]
AID - 10.1016/j.ebiom.2019.05.032 [doi]
PST - ppublish
SO  - EBioMedicine. 2019 Jun;44:182-193. doi: 10.1016/j.ebiom.2019.05.032. Epub 2019 
      May 31.